Oxime

Odyssey Health, Inc. To Develop Intranasal Field- Deliverable Nerve Agent Antidote

Retrieved on: 
Thursday, January 12, 2023
Odyssey, Seizure, Central nervous system depression, Oxime, Brain, Pain, Infection, Chemical warfare, Olfactory nerve, OTC, Nerve agent, Death, Risk, Chemical substance, Nerve, Plasma, Central nervous system, Smell, Human, Vaccine

Las Vegas Nevada, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, announces the launch of a concept phase to develop an intra-nasal field-deliverable nerve agent antidote.

Key Points: 
  • Las Vegas Nevada, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, announces the launch of a concept phase to develop an intra-nasal field-deliverable nerve agent antidote.
  • Nerve agents kill brain cells leading to respiratory failure, seizures, and death within minutes of exposure.
  • Previous work in humans completed by Odyssey has shown that intranasal administration of spray-dried powders leads to low plasma concentrations compared to an intravenous route.
  • Oximes are an antidote for organophosphate nerve agents however the current application is through a skin auto-injector.